论文部分内容阅读
目的:观察重用黄芪自拟方联合奥拉西坦胶囊对脑卒中后痴呆患者高级脑功能的影响。方法:选取92例脑卒中后痴呆患者作为研究对象,按随机数字表法分为研究组和对照组各46例。对照组予以奥拉西坦胶囊治疗,研究组在对照组用药基础上加用重用黄芪自拟方治疗。比较2组临床疗效,评估2组治疗前后的痴呆程度以及认知功能和记忆功能,检测2组治疗前后超氧化物歧化酶(SOD)和血浆脂质过氧化物(LPO)含量。结果:总有效率研究组为89.13%,高于对照组的69.57%,2组比较,差异有统计学意义(P<0.05)。治疗前,2组长谷川量表(HDS)、简易智能表(MMSE)、韦氏记忆测验(WMS)评分比较,差异均无统计学意义(P>0.05)。治疗后,2组HDS、MMSE、WMS评分均较治疗前升高(P<0.05),研究组的各项评分均高于对照组(P<0.05)。治疗前,2组SOD、LPO含量比较,差异均无统计学意义(P>0.05)。治疗后,2组SOD含量均较治疗前升高(P<0.05),LPO含量均较治疗前降低(P<0.05),研究组SOD含量高于对照组(P<0.05),LPO含量低于对照组(P<0.05)。结论:重用黄芪自拟方联合奥拉西坦胶囊能够改善脑卒中后痴呆患者的痴呆症状、认知功能和记忆功能,临床疗效显著。
Objective: To observe the effect of reusing Astragalus prescription combined with Oxiracetam on advanced brain function in patients with post-stroke dementia. Methods: Ninety-two patients with post-stroke dementia were selected as study subjects and divided into study group (46 cases) and control group (46 cases) according to random number table. The control group was treated with Oxiracetam capsules, and the study group was treated with the recurrent astragalus prescription on the basis of the control group. The clinical efficacy of the two groups were compared. The degree of dementia and the cognitive function and memory function of the two groups before and after treatment were evaluated. The levels of superoxide dismutase (SOD) and plasma lipid peroxidation (LPO) were measured before and after treatment. Results: The total effective rate was 89.13% in the study group and 69.57% in the control group. There was significant difference between the two groups (P <0.05). Before treatment, there were no significant differences between the two groups in HDS, MMSE and WMS scores (P> 0.05). After treatment, the scores of HDS, MMSE and WMS in both groups were significantly higher than those before treatment (P <0.05). All the scores in the study group were higher than those in the control group (P <0.05). Before treatment, there was no significant difference in the contents of SOD and LPO between the two groups (P> 0.05). After treatment, the content of SOD in both groups increased (P <0.05) and the content of LPO decreased (P <0.05), and the content of SOD in the study group was higher than that in the control group (P <0.05) Control group (P <0.05). Conclusion: Reuse of astragalus prescription combined with Oxiracetam can improve dementia symptoms, cognitive function and memory function in patients with post-stroke dementia. The clinical efficacy is significant.